Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides

Acquisition of a mucoid phenotype by Pseudomonas sp. in the lungs of cystic fibrosis (CF) patients, with subsequent over-production of extracellular polymeric substance (EPS), plays an important role in mediating the persistence of multi-drug resistant (MDR) infections. The ability of a low molecular weight (Mn = 3200 g mol−1) alginate oligomer (OligoG CF-5/20) to modify biofilm structure of mucoid Pseudomonas aeruginosa (NH57388A) was studied in vitro using scanning electron microscopy (SEM), confocal laser scanning microscopy (CLSM) with Texas Red (TxRd®)-labelled OligoG and EPS histochemical staining. Structural changes in treated biofilms were quantified using COMSTAT image-analysis software of CLSM z-stack images, and nanoparticle diffusion. Interactions between the oligomers, Ca2+ and DNA were studied using molecular dynamics (MD) simulations, Fourier transform infrared spectroscopy (FTIR) and isothermal titration calorimetry (ITC). Imaging demonstrated that OligoG treatment (≥0.5%) inhibited biofilm formation, revealing a significant reduction in both biomass and biofilm height (P < 0.05). TxRd®-labelled oligomers readily diffused into established (24 h) biofilms. OligoG treatment (≥2%) induced alterations in the EPS of established biofilms; significantly reducing the structural quantities of EPS polysaccharides, and extracellular (e)DNA (P < 0.05) with a corresponding increase in nanoparticle diffusion (P < 0.05) and antibiotic efficacy against established biofilms. ITC demonstrated an absence of rapid complex formation between DNA and OligoG and confirmed the interactions of OligoG with Ca2+ evident in FTIR and MD modelling. The ability of OligoG to diffuse into biofilms, potentiate antibiotic activity, disrupt DNA-Ca2+-DNA bridges and biofilm EPS matrix highlights its potential for the treatment of biofilm-related infections.Drug-resistant biofilms: Marine algal molecules could helpSmall carbohydrate molecules derived from marine algae show potential for inhibiting biofilm formation in multi-drug resistant infections. A research team led by Lydia Powell at Cardiff University, UK, investigated the action of carbohydrates called alginate oligosaccharides, composed of a small number of linked sugar molecules. The oligosaccharides modified and disrupted the structure of cultured biofilms of Pseudomonas aeruginosa, the cause of many serious drug resistant infections. This effect significantly inhibited the formation and maintenance of the biofilm state, which is known to be a crucial factor allowing the bacteria to resist drug treatment. Antibiotics proved more effective following the oligosaccharide intervention. The researchers uncovered key molecular details involved in the ability of the oligosaccharides to diffuse into and disrupt biofilms. The therapeutic potential of these small carbohydrates is currently being investigated in clinical trials.

[1]  S. Sze,et al.  Selective labelling and eradication of antibiotic-tolerant bacterial populations in Pseudomonas aeruginosa biofilms , 2016, Nature Communications.

[2]  C. Wright,et al.  A nanoscale characterization of the interaction of a novel alginate oligomer with the cell surface and motility of Pseudomonas aeruginosa. , 2014, American journal of respiratory cell and molecular biology.

[3]  K. Beck,et al.  A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness , 2017, Antimicrobial Agents and Chemotherapy.

[4]  G. Wong,et al.  The Pel Polysaccharide Can Serve a Structural and Protective Role in the Biofilm Matrix of Pseudomonas aeruginosa , 2011, PLoS pathogens.

[5]  P. Russo,et al.  Gentamicin and leucine inhalable powder: what about antipseudomonal activity and permeation through cystic fibrosis mucus? , 2013, International journal of pharmaceutics.

[6]  James P. Folsom,et al.  Contribution of Stress Responses to Antibiotic Tolerance in Pseudomonas aeruginosa Biofilms , 2015, Antimicrobial Agents and Chemotherapy.

[7]  N. Høiby,et al.  Genome Sequence of Pseudomonas aeruginosa Strain DK1-NH57388A, a Stable Mucoid Cystic Fibrosis Isolate , 2016, Genome Announcements.

[8]  Matthew R. Parsek,et al.  Pseudomonas aeruginosa Rugose Small-Colony Variants Have Adaptations That Likely Promote Persistence in the Cystic Fibrosis Lung , 2009, Journal of bacteriology.

[9]  Hans-Curt Flemming,et al.  The EPS Matrix: The “House of Biofilm Cells” , 2007, Journal of bacteriology.

[10]  Hans-Curt Flemming,et al.  13C-NMR study of the interaction of bacterial alginate with bivalent cations. , 2003, International journal of biological macromolecules.

[11]  N. Høiby,et al.  OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model , 2016, Antimicrobial Agents and Chemotherapy.

[12]  K. Siddiqui,et al.  Influence of Calcium in Extracellular DNA Mediated Bacterial Aggregation and Biofilm Formation , 2014, PloS one.

[13]  N. Buurma,et al.  Rhenium complexes of chromophore-appended dipicolylamine ligands: syntheses, spectroscopic properties, DNA binding and X-ray crystal structure , 2008 .

[14]  Boo Shan Tseng,et al.  Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix , 2015, Proceedings of the National Academy of Sciences.

[15]  E. Greenberg,et al.  Chelator-Induced Dispersal and Killing of Pseudomonas aeruginosa Cells in a Biofilm , 2006, Applied and Environmental Microbiology.

[16]  P. Stewart,et al.  A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance , 2003, Nature.

[17]  M. Parsek,et al.  The roles of biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms. , 2012, FEMS immunology and medical microbiology.

[18]  N. Høiby,et al.  The phenotypic evolution of Pseudomonas aeruginosa populations changes in the presence of subinhibitory concentrations of ciprofloxacin. , 2016, Microbiology.

[19]  S. Molin,et al.  The clinical impact of bacterial biofilms , 2011, International Journal of Oral Science.

[20]  M. Caldara,et al.  The Extracellular Matrix Component Psl Provides Fast-Acting Antibiotic Defense in Pseudomonas aeruginosa Biofilms , 2013, PLoS pathogens.

[21]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[22]  M. Parsek,et al.  Analysis of Pseudomonas aeruginosa Conditional Psl Variants Reveals Roles for the Psl Polysaccharide in Adhesion and Maintaining Biofilm Structure Postattachment , 2006, Journal of bacteriology.

[23]  P. Bremer,et al.  The effect of alginate lyase on the gentamicin resistance of Pseudomonas aeruginosa in mucoid biofilms , 2016, Journal of applied microbiology.

[24]  K. Draget,et al.  Oligoguluronate induced competitive displacement of mucin–alginate interactions: relevance for mucolytic function , 2012 .

[25]  J. Roberts,et al.  An in vitro study of alginate oligomer therapies on oral biofilms. , 2013, Journal of dentistry.

[26]  Matthew R. Parsek,et al.  Assembly and Development of the Pseudomonas aeruginosa Biofilm Matrix , 2009, PLoS pathogens.

[27]  Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms , 2015 .

[28]  M. Drumm,et al.  A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[29]  K. Beck,et al.  Alginate Oligosaccharide-Induced Modification of the lasI-lasR and rhlI-rhlR Quorum-Sensing Systems in Pseudomonas aeruginosa , 2018, Antimicrobial Agents and Chemotherapy.

[30]  T. Tolker-Nielsen,et al.  Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. , 2015, Advanced drug delivery reviews.

[31]  S. Bell,et al.  Elevated metal concentrations in the CF airway correlate with cellular injury and disease severity. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[32]  C. Wright,et al.  The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms , 2013, Biofouling.

[33]  D. Wozniak,et al.  Understanding the control of Pseudomonas aeruginosa alginate synthesis and the prospects for management of chronic infections in cystic fibrosis , 2005, Molecular microbiology.

[34]  A. Linker,et al.  Production and Characterization of the Slime Polysaccharide of Pseudomonas aeruginosa , 1973, Journal of bacteriology.

[35]  S. Molin,et al.  Novel Mouse Model of Chronic Pseudomonas aeruginosa Lung Infection Mimicking Cystic Fibrosis , 2005, Infection and Immunity.

[36]  J. Elborn,et al.  Treatment of lung infection in patients with cystic fibrosis: current and future strategies. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[37]  Yang Shen,et al.  Purification and Characterization of Biofilm-Associated EPS Exopolysaccharides from ESKAPE Organisms and Other Pathogens , 2013, PloS one.

[38]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[39]  C. Wright,et al.  A New Class of Safe Oligosaccharide Polymer Therapy To Modify the Mucus Barrier of Chronic Respiratory Disease. , 2016, Molecular pharmaceutics.

[40]  N. Høiby,et al.  Pseudomonas aeruginosa biofilms in cystic fibrosis. , 2010, Future microbiology.

[41]  M. Schurr,et al.  Iron-Regulated Expression of Alginate Production, Mucoid Phenotype, and Biofilm Formation by Pseudomonas aeruginosa , 2014, mBio.

[42]  Yang Liang,et al.  Mechanical properties of the superficial biofilm layer determine the architecture of biofilms. , 2016, Soft matter.

[43]  C. Jang,et al.  Modeling and Re-Engineering of Azotobacter vinelandii Alginate Lyase to Enhance Its Catalytic Efficiency for Accelerating Biofilm Degradation , 2016, PloS one.

[44]  C. Whitfield,et al.  Biosynthesis of the Pseudomonas aeruginosa Extracellular Polysaccharides, Alginate, Pel, and Psl , 2011, Front. Microbio..

[45]  G. Tetz,et al.  Effect of DNase and Antibiotics on Biofilm Characteristics , 2008, Antimicrobial Agents and Chemotherapy.

[46]  R. Meyer,et al.  Evaluation of fluorescent stains for visualizing extracellular DNA in biofilms. , 2014, Journal of microbiological methods.

[47]  M. Hentzer,et al.  Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr−/− Mice , 2007, Antimicrobial Agents and Chemotherapy.

[48]  Leo Eberl,et al.  Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. , 2002, Microbiology.

[49]  S. Molin,et al.  Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis , 2014, Nature Genetics.

[50]  D. Nivens,et al.  Calcium-Induced Virulence Factors Associated with the Extracellular Matrix of Mucoid Pseudomonas aeruginosa Biofilms , 2005, Journal of bacteriology.

[51]  B. Ersbøll,et al.  Quantification of biofilm structures by the novel computer program COMSTAT. , 2000, Microbiology.

[52]  Mark Gumbleton,et al.  Methods to determine the interactions of micro- and nanoparticles with mucus. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[53]  J. Emerson,et al.  Clinically Feasible Biofilm Susceptibility Assay for Isolates of Pseudomonas aeruginosa from Patients with Cystic Fibrosis , 2004, Journal of Clinical Microbiology.

[54]  B. Jana,et al.  In vitro interaction between calf thymus DNA and Escherichia coli LPS in the presence of divalent cation Ca2+. , 2008, Biopolymers.

[55]  J. Mattick,et al.  Extracellular DNA required for bacterial biofilm formation. , 2002, Science.

[56]  S. Kjelleberg,et al.  A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms , 2006, Molecular microbiology.

[57]  O. Smidsrod,et al.  Molecular basis for some physical properties of alginates in the gel state , 1974 .

[58]  N. Buurma,et al.  The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption , 2017, Scientific Reports.

[59]  A. Tøndervik,et al.  Overcoming Drug Resistance with Alginate Oligosaccharides Able To Potentiate the Action of Selected Antibiotics , 2012, Antimicrobial Agents and Chemotherapy.

[60]  G. Skjåk-Bræk,et al.  OligoG CF‐5/20 normalizes cystic fibrosis mucus by chelating calcium , 2017, Clinical and experimental pharmacology & physiology.

[61]  D. Allison,et al.  The Biofilm Matrix , 2003, Biofouling.

[62]  K. Lewis.  Persister cells, dormancy and infectious disease , 2007, Nature Reviews Microbiology.

[63]  G. Pier,et al.  Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. , 1995, Journal of immunology.

[64]  V. Deretic,et al.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. , 1996, Microbiological reviews.

[65]  Jost Wingender,et al.  Application of fluorescently labelled lectins for the visualization and biochemical characterization of polysaccharides in biofilms of Pseudomonas aeruginosa. , 2002, Journal of microbiological methods.

[66]  B. Rehm,et al.  Expression of the psl Operon in Pseudomonas aeruginosa PAO1 Biofilms: PslA Performs an Essential Function in Biofilm Formation , 2005, Applied and Environmental Microbiology.

[67]  H. Domínguez,et al.  Antimicrobial Action of Compounds from Marine Seaweed , 2016, Marine drugs.

[68]  H C van der Mei,et al.  Physico-chemistry of initial microbial adhesive interactions--its mechanisms and methods for study. , 1999, FEMS microbiology reviews.

[69]  H. Tiddens,et al.  The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug? , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[70]  H. Ceri,et al.  The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms , 1999, Journal of Clinical Microbiology.

[71]  G. Skjåk-Bræk,et al.  On the initial binding of alginate by calcium ions. The tilted egg-box hypothesis. , 2013, The journal of physical chemistry. B.

[72]  N. Høiby,et al.  Strategies for combating bacterial biofilm infections , 2014, International Journal of Oral Science.

[73]  K. Rumbaugh,et al.  Synergistic Interactions of Pseudomonas aeruginosa and Staphylococcus aureus in an In Vitro Wound Model , 2014, Infection and Immunity.

[74]  S. Lewenza,et al.  Extracellular DNA Chelates Cations and Induces Antibiotic Resistance in Pseudomonas aeruginosa Biofilms , 2008, PLoS pathogens.

[75]  M. Elimelech,et al.  Calcium and magnesium cations enhance the adhesion of motile and nonmotile pseudomonas aeruginosa on alginate films. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[76]  U. Jenal,et al.  LadS is a calcium-responsive kinase that induces acute-to-chronic virulence switch in Pseudomonas aeruginosa , 2016, Nature Microbiology.